Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—
−5.35USD
−241.36 MUSD
1.80 MUSD
38.77 M
About INHIBRX INC. DL -,0001
Sector
Industry
CEO
Mark P. Lappe
Website
Headquarters
La Jolla
Employees (FY)
172
Founded
2010
Inhibrx, Inc., is a clinical stage biotechnology company, focuses on developing pipeline of novel biologic therapeutic candidates. The firm’s pipeline is focused on oncology, orphan diseases and infectious diseases. It utilizes diverse methods of protein engineering to address the specific requirements of complex target and disease biology, including its proprietary sdAb platform. The company was founded by Mark Paul Lappe, Quinn Deveraux and Brendan P. Eckelman in April 2010 and is headquartered La Jolla, CA.
Trade directly on the supercharts through our supported, fully-verified and user-reviewed brokers.
Frequently Asked Questions
The current price of INBX is 16.25 USD — it has decreased by 52.36% in the past 24 hours. Watch Inhibrx Biosciences, Inc. stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on NASDAQ exchange Inhibrx Biosciences, Inc. stocks are traded under the ticker INBX.
INBX stock has fallen by 52.50% compared to the previous week, the month change is a 52.51% fall, over the last year Inhibrx Biosciences, Inc. has showed a 31.69% decrease.
INBX reached its all-time high on Dec 18, 2020 with the price of 50.97 USD, and its all-time low was 7.67 USD and was reached on Jun 16, 2022. View more price dynamics on INBX chart.
See other stocks reaching their highest and lowest prices.
See other stocks reaching their highest and lowest prices.
INBX stock is 123.67% volatile and has beta coefficient of 2.61. Track Inhibrx Biosciences, Inc. stock price on the chart and check out the list of the most volatile stocks — is Inhibrx Biosciences, Inc. there?
Yes, you can track Inhibrx Biosciences, Inc. financials in yearly and quarterly reports right on TradingView.
INBX net income for the last quarter is −78.71 M USD, while the quarter before that showed −93.60 M USD of net income which accounts for 15.91% change. Track more Inhibrx Biosciences, Inc. financial stats to get the full picture.
No, INBX doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
As of Jun 1, 2024, the company has 172.00 employees. See our rating of the largest employees — is Inhibrx Biosciences, Inc. on this list?
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. Inhibrx Biosciences, Inc. EBITDA is −247.59 M USD, and current EBITDA margin is −12.11 K%. See more stats in Inhibrx Biosciences, Inc. financial statements.
Like other stocks, INBX shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade Inhibrx Biosciences, Inc. stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So Inhibrx Biosciences, Inc. technincal analysis shows the strong sell today, and its 1 week rating is strong sell. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating Inhibrx Biosciences, Inc. stock shows the sell signal. See more of Inhibrx Biosciences, Inc. technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.
If you're still not sure, try looking for inspiration in our curated watchlists.